Minaris and LIfT BioSciences collaborate in cell therapy development
CDMO Minaris Regenerative Medicine GmbH is to manufacture the leukocyte infusion therapy N-LIfT for LIFT BioSciences.
LIfT BioSciences wants to start its first-in-human clinical trials with an allogeneic neutrophil progenitor-based cell therapy in first Quartal of 2024 in Europe. As the company needs to have a Good Manufacturing Practice (GMP)-compliant manufacturing process for its product it has selected Minaris Regenerative Medicine as its contract manufacturing partner.
N-LIfT is a first-in-class neutrophil progenitor-based Leukocyte Infusion Therapy (LIfT) for the treatment of various solid cancers, like pancreatic, lung Cancer etc. N-LIfT is made from Immunomodulatory alpha neutrophils committed myeloid progenitors (IMANp) that are manufactured ex vivo from hematopoietic stem cells (HSCs) of healthy donors who exhibit exceptional innate cancer killing properties. The cell therapy works through the innate immune pathway and activates the adaptive immune system.
Alex Blyth, CEO of LIfT BioSciences comment: We are confident that Minaris extensive track record in process development, clinical, and commercial manufacturing will generate a scalable and cost-effective GMP-process and accelerate our clinical readiness.
Dusan Kosijer, CEO of Minaris is excited about the new partnership and to contribute to scientific progress.
